Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
about
Insights into bombesin receptors and ligands: Highlighting recent advancesSmall bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.Peptide analogs in the therapy of prostate cancer.Bombesin receptor-mediated imaging and cytotoxicity: review and current statusTherapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Breast cancer cell-associated endopeptidase EC 24.11 modulates proliferative response to bombesinTargeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.Peptide-mediated targeted drug delivery.Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.The Escherichia coli copper-responsive copA promoter is activated by gold.
P2860
Q28081153-312DEF3A-86A4-4BA0-B820-0B4AEF1DDF3DQ33853729-CB374400-9D7E-4E07-9DC7-946AF932F2D4Q34057795-E013CFBC-FC03-49C5-9A79-AFCA20D61933Q34684387-A88AF222-9F89-41AF-9662-D6FAC437147AQ34772221-8D8C7A63-C67A-4EA6-9255-9249449A4F3CQ34979199-95D46924-E76E-4C82-B6FC-326F39B6F5BCQ35891113-5747C9C3-E10C-4B64-906F-82BC5602D0F4Q36617395-DCC06C2F-2EBB-4491-9084-9AEDB5A3F6F2Q36619952-2603A967-F993-4E4A-936E-FD0AA159E269Q36644341-848BF9A3-7370-4263-8B50-344C2743588CQ36748502-A34EDD91-120C-47BC-9C43-F595FCC82059Q37083440-6EC7ED4A-37A7-4A0D-92AC-786945FD05DCQ37196815-ABC6272A-B7A9-42B7-A5CE-25D07697BE8EQ37785045-C9B52216-F866-4EEF-AEAF-5F69C07D3E53Q42795202-57E4027D-F9B5-4818-A9EA-685D963D010CQ50865530-F31C2283-0CC6-48CE-B611-C87468ABC60CQ54534686-39FE7578-A812-4F9E-8955-D39C4DCDD49D
P2860
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@ast
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@en
type
label
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@ast
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@en
prefLabel
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@ast
Design, synthesis, and in vitr ...... ative, 2-pyrrolinodoxorubicin.
@en
P2093
P2860
P356
P1476
Design, synthesis, and in vitr ...... vative, 2-pyrrolinodoxorubicin
@en
P2093
P2860
P304
P356
10.1073/PNAS.94.2.652
P407
P577
1997-01-01T00:00:00Z